Navigation Links
NeuroSigma, Inc. Retains CCG Investor Relations
Date:4/4/2011

LOS ANGELES, April 4, 2011 /PRNewswire/ -- NeuroSigma, Inc. ("NeuroSigma"), a Los Angeles-based medical technology company established to in-license and develop early stage technologies with the potential to transform medical practice, today announced that it has retained CCG Investor Relations to design and execute its strategic communications and investor relations campaign.

"We look forward to working closely with CCG to establish and enhance our profile in the investment community and with all our stakeholders," said Lodwrick M. Cook, Chairman of NeuroSigma.

"Given CCG's track record of professional experience representing a wide spectrum of high-growth, U.S. companies, we are confident that our new partnership will help us achieve those goals," added Dr. Leon Ekchian, President and CEO of NeuroSigma.

Founded by experts in business management and the healthcare industry, NeuroSigma has a growing pipeline of therapies in clinical trials targeting epilepsy, depression, post-traumatic stress disorder (PTSD), and obesity, among others.  NeuroSigma is actively engaged in cutting-edge preclinical research and development, as well as groundbreaking Phase I and Phase II clinical trials at the University of California, Los Angeles (UCLA) and is currently utilizing two distinct therapy platforms:

Trigeminal Nerve Stimulation (TNS) - A proprietary therapy developed at UCLA and exclusively licensed to NeuroSigma.

Deep Brain Stimulation (DBS) – NeuroSigma is supporting the development of new therapies for this platform, which was originally pioneered in France for the treatment of essential tremor and Parkinson's disease.

"We are very pleased to be working with NeuroSigma," said William Coffin, Chairman of CCG Investor Relations.  "At a time when translating important medical research from 'lab bench to bedside' has never been more valuable, NeuroSigma is providing that expertise, working with the very best at institutions like UCLA and bringing their pioneering work to the marketplace for commercialization.  The Company is initially focused on several very important conditions, including epilepsy, which affects 3 million people in the United States and over 50 million worldwide, and major depression, affecting over 18 million American adults and over 120 million worldwide.  With its current team and strong development processes in place, the Company is well positioned for the future."

About NeuroSigma

NeuroSigma is a Los Angeles-based medical technology company established to in-license and develop early stage technologies with the potential to transform medical practice.  Currently we have a specific focus on neuromodulation.  NeuroSigma employs two therapy platforms: Trigeminal Nerve Stimulation (TNS) and Deep Brain Stimulation (DBS).  NeuroSigma has amassed a significant intellectual property portfolio, primarily licensed from the University of California, Los Angeles on a world-wide exclusive basis, including potential therapies for epilepsy, depression and post-traumatic stress disorder (PTSD) via TNS and for PTSD, obesity and cachexia via DBS.  More information about NeuroSigma is online at http://www.neurosigma.com/

About CCG Investor Relations

CCG is a leading global investor relations and strategic communications consulting firm.  In business for more than 30 years, the agency provides a complete range of strategic and investor communications, through our global network to over 100 clients across multiple capital markets.  CCG has been awarded a number of industry honors for its handling of complex investor relations communications matters.  The agency's corporate headquarters is in Los Angeles with additional offices in New York, Beijing, Shanghai, Hong Kong, London, and Tel Aviv.  For further information, contact CCG directly, or visit the Company's web site at http://www.ccgir.com/


'/>"/>
SOURCE NeuroSigma, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. BioDrain Medical, Inc. Retains CFSG1 as Its U.S. Investor Relations Firm
2. Dehaier Medical Retains The Piacente Group as Strategic Investor Relations Consulting Firm
3. SCOLR Pharma, Inc. Retains Nicholas Hall & Company
4. Xenogenics Corporation Retains the Emmes Group to Advise on Fund Raising Efforts
5. Independent Committee of Caraco Board Retains Independent Advisors for Consideration of Sun Pharma Proposal to Purchase Outstanding Shares and Caraco Acknowledges Filing of Purported Class Action Lawsuits
6. Lotus Pharmaceuticals Retains Sichenzia Ross Friedman Ference LLP as General Legal Counsel
7. Anadys Retains Lazard as Strategic Advisor
8. Connectyx Retains Services of CP Capital Securities as It Expands Its Presence in the $5 Billion US Electronic Health Record Market
9. China Pharma Holdings, Inc. Retains CCG Investor Relations
10. Ampio Pharmaceuticals, Inc. Retains Redwood Consultants, LLC to Assist in Shareholder Relations and Strategic Planning
11. Solos Endoscopy, Inc. Retains Expert Resource to Meet Requirements for ISO 13485 Quality Management System Initiative
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/25/2017)... 2017   Montrium , an industry leader ... the IQPC Trial Master Files & Inspection Readiness ... EastHORN Clinical Services has selected eTMF Connect ... management. EastHORN, a leading European contract research organization ... transparency to enable greater collaboration with sponsors, improve ...
(Date:9/22/2017)... Sept. 22, 2017 AVACEN Medical (AVACEN) announced ... now successfully helping those with the widespread pain associated ... diagnosed Amanda in Essex, England ... my hair, experiencing no sleep at all, tremendous pain, ... I cannot recommend [the AVACEN 100] enough, how this ...
(Date:9/18/2017)... R.I. , Sept. 18, 2017 /PRNewswire/ ... the fields of bioinformatics and immune engineering, ... a protective avian influenza A (H7N9) vaccine. ... distantly related to seasonal influenza and presents ... rely on prior exposure to be effective. ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... October 13, 2017 , ... The Visiting Nurse Association (VNA) ... a collection of specialty vendors and unique items from across the nation, this holiday-themed ... and wellness services offered by the VNA. The boutique will be open Saturday, ...
(Date:10/13/2017)... ... October 13, 2017 , ... Coveros, a ... has been awarded a contract by the Center for Medicare and Medicaid Services ... accelerate the enterprise use of Agile methodologies in a consistent and high value ...
(Date:10/12/2017)... Orleans, LA (PRWEB) , ... October 12, 2017 , ... ... centers in the U.S., announced today its plans to open a flagship location in ... will occupy the former Rooms To Go store next to Office Depot in the ...
(Date:10/12/2017)... ... 2017 , ... Information about the technology: , Otomagnetics has ... prevention of a major side effect of chemotherapy in children. Cisplatin and carboplatin ... cisplatin, hearing loss is FDA listed on-label as a dose limiting toxicity. Hearing ...
(Date:10/12/2017)... ... October 12, 2017 , ... Women-owned ... Michigan’s 2017 Best and Brightest in Wellness® by Best and Brightest. OnSite Wellness ... on Friday, Oct. 20 from 7:30 a.m. to 2 p.m. at the Henry ...
Breaking Medicine News(10 mins):